Acexamic Acid
CAS 57-08-9
Acexamic Acid (CAS 57-08-9) is a Phase 3 pharmaceutical compound with 3 bioactivity targets and 94 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 27861.4375 nM | 32 | - |
| - | IC50 | 19976.309999999998 nM | 1 | - |
| - | Potency | 22387.2 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Acexamic Acid used for in pharmaceutical contexts?
Acexamic Acid (CAS 57-08-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Acexamic Acid?
Acexamic Acid has 94 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal pain lower, Acute myeloid leukaemia, Anaemia, Asthenia, Bradykinesia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Acexamic Acid also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Acetamidocaproic Acid with EU status "permitted".
What clinical phase is Acexamic Acid in?
Acexamic Acid is rendered with ChEMBL max phase 3.